Floatz logo

Sigvotatug Vedotin

Uterine Cervical Neoplasms

Seagen, a wholly owned subsidiary of Pfizerantibody_drug_conjugatePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Uterine Cervical Neoplasms cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
GV20 Therapeutics
Phase 3BB
Carboplatin
Eli Lilly and Company
Phase 2B
FULVESTRANT
Atavistik Bio, Inc
Phase 2B
LENVATINIB
Merck Sharp & Dohme LLC
Phase 2B

View all 29 →

Same molecule, other indications

Sigvotatug Vedotin is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
skin squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →